Google
Trusted Resources: News & Events
Latest announcements and gatherings
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study evaluating voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD), has completed its first scheduled clinical safety review. No drug-related serious or severe adverse events were reported in either of the voxelotor treatment arms (900 mg and 1500 mg), and there were no discontinuations due to adverse events. Based on this review, the DSMB did not identify safety concerns with voxelotor at either dose level across all patients dosed in the ongoing SCD clinical program, including adult patients in the Phase 3 HOPE Study and adolescent patients in the HOPE-KIDS 1 (GBT440-007) Study. Based on the available safety data to date, including at the high dose level of 1500 mg, the DSMB recommended that the pivotal study continue as planned and approved initiation of enrollment in adolescent patients age 12 to 17.
+myBinderRelated Content
-
Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (...BACKGROUND: Little is known about red b...
-
Partnership to Ensure Supply of LentiGlobin, Potential Gene TherapyBluebird Bio extended a partnership with...
-
Pediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
-
Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
-
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
-
New Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
-
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.